Contact Us
Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2025
Global Non-Alcoholic Steatohepatitis Biomarkers Market Report 2025

Report Price : $4490.00

Pages : 200

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2025

By Type (Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types), By Disease (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity), By End Use (Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Non-Alcoholic Steatohepatitis Biomarkers Market Overview

• Non-Alcoholic Steatohepatitis Biomarkers market size has reached to $1.36 billion in 2024

• Expected to grow to $3.81 billion in 2029 at a compound annual growth rate (CAGR) of 22.6%

• Growth Driver: Rising Liver Cancer Prevalence Fuels Expansion Of Non-Alcoholic Steatohepatitis Biomarkers Market

• Market Trend: Advancements In Nis4 Technology Pave The Way For Innovative Blood-Based Molecular Diagnostic Test

North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Non-Alcoholic Steatohepatitis Biomarkers Market?

Non-alcoholic steatohepatitis (NASH) is a type of liver inflammation and damage caused by a build-up of fat in the liver. NASH biomarkers are used as diagnostic tools to assess the severity of non-alcoholic steatohepatitis and to assess liver damage. This damages the liver cells and inflames the liver, which can result in cirrhosis (liver scarring) and liver failure. Biomarkers refer to a particular quality that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment.

The main types of non-alcoholic steatohepatitis biomarkers include hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers and others. Hepatic fibrosis biomarkers refer to biomarkers for hepatic fibrosis, an overly exuberant wound healing in which excessive connective tissue develops in the liver. They are used to treat different diseases including hypertension, heart disease, high blood lipid, type 2 diabetes and obesity for use by various end-uses such as research institutes and academics, diagnostic centers, pharmaceutical companies and contract research organizations (CROs), hospitals and clinics and others.

Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2025 Market Size and growth rate 2025 to 2029: Graph

What Is The Non-Alcoholic Steatohepatitis Biomarkers Market Size 2025 And Growth Rate?

The non-alcoholic steatohepatitis biomarkers market size has grown exponentially in recent years. It will grow from $1.36 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 23.9%. The growth in the historic period can be attributed to diabetes and metabolic syndrome, awareness and screening programs, liver biopsy limitations, regulatory support, shift towards personalized medicine, clinical trials in NASH.

What Is The Non-Alcoholic Steatohepatitis Biomarkers Market Growth Forecast?

The non-alcoholic steatohepatitis biomarkers market size is expected to see exponential growth in the next few years. It will grow to $3.81 billion in 2029 at a compound annual growth rate (CAGR) of 22.6%. The growth in the forecast period can be attributed to emergence of novel therapies, expansion of precision medicine approaches, patient advocacy initiatives, integration of multi-omics data, enhanced patient engagement. Major trends in the forecast period include telemedicine and remote monitoring, innovative diagnostic platforms, global collaborations in research, technological advancements in biomarker discovery, integration of artificial intelligence (AI), inclusion of imaging biomarkers.

The forecast of 22.6% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through tariffs on specialized enzyme-linked immunosorbent assay (ELISA) assay kits from Sweden, increasing costs for liver disease diagnostics and delaying early detection of metabolic liver conditions.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Medical Equipment Industry?

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

How Is The Non-Alcoholic Steatohepatitis Biomarkers Market Segmented?

1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types

2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses

Subsegments:

1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index

2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin

3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)

4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)

5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers

What Is Driving The Non-Alcoholic Steatohepatitis Biomarkers Market? Rising Liver Cancer Prevalence Fuels Expansion Of Non-Alcoholic Steatohepatitis Biomarkers Market

The growing prevalence of liver cancer is expected to propel the growth of the non-alcoholic steatohepatitis biomarkers market going forward. Liver cancer refers to the development of malignant tumors within the liver and can start in the liver itself (primary liver cancer) or spread to the liver from other parts of the body (secondary or metastatic liver cancer). Non-alcoholic steatohepatitis (NASH) biomarkers are used in liver cancer for early detection, disease progression monitoring, and treatment response assessment, to provide prognostic information, and can help reduce the need for invasive procedures. For instance, in 2022, according to the World Cancer Research Fund, a UK-based not-for-profit organization, there were approximately 866,136 new cases of liver cancer worldwide, with liver cancer being the 6th most common cancer globally. Therefore, the growing prevalence of liver cancer is driving the growth of the non-alcoholic steatohepatitis biomarkers industry.

What Is Driving The Non-Alcoholic Steatohepatitis Biomarkers Market? Rising Demand For Personalized Medicine Fuels Growth In Non-Alcoholic Steatohepatitis Biomarkers Market

The growing demand for personalized medicine is expected to propel the growth of the non-alcoholic steatohepatitis biomarkers market going forward. Personalized medicine refers to an innovative approach to medical treatment and healthcare that tailors medical decisions, practices, interventions, and drug therapies to the individual patient. Personalized medicine in non-alcoholic steatohepatitis (NASH) biomarkers offer precise and individualized diagnosis, development of tailored treatment strategies, optimize drug selection, monitoring of treatment responses, and minimize adverse effects and complications. For instance, in October 2022, according to reports published by STAT, a US-based health-oriented news company, there were more than 75,000 genetic testing products and 300 personalized medicines. Therefore, the growing demand for personalized medicine is driving the growth of the non-alcoholic steatohepatitis biomarkers industry.

Who Are The Major Players In The Global Non-Alcoholic Steatohepatitis Biomarkers Market?

Major companies operating in the non-alcoholic steatohepatitis biomarkers market include Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine

What Are The Key Trends Of The Global Non-Alcoholic Steatohepatitis Biomarkers Market? Advancements In Nis4 Technology Pave The Way For Innovative Blood-Based Molecular Diagnostic Test

Technological advancements are a key trend in gaining popularity in the non-alcoholic steatohepatitis biomarkers market. Major companies operating in the non-alcoholic steatohepatitis biomarkers market are focused on developing innovative solutions to strengthen their position in the market. For instance, in October 2022, GENFIT, a France-based late-stage biopharmaceutical company, and LabCorp, a US-based life sciences company, agreed on a five-year exclusive licensing deal for GENFIT's NIS4 technology to aid in identifying patients with non-alcoholic-steatohepatitis-at-risk (NASH). NIS4 technology is an innovative, multi-biomarker-based algorithm specifically developed to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F > 2), also referred to as at-risk NASH. As part of the agreement, LabCorp will develop and commercialize a blood-based molecular diagnostic test utilizing NIS4 technology in the United States and Canada, giving widespread access to healthcare professionals.

What Are The Key Trends Of The Global Non-Alcoholic Steatohepatitis Biomarkers Market? Advancements In NASH Biomarkers The ELF Test And Its Impact On Patient Care

Major companies operating in the non-alcoholic steatohepatitis biomarkers market focus on introducing ELF tests to improve the diagnosis and monitoring of liver fibrosis, which is a key feature of NASH. The ELF Test is a blood-based diagnostic tool intended to assess the prognosis for patients with advanced fibrosis (F3 or F4) caused by non-alcoholic steatohepatitis (NASH), a type of non-alcoholic fatty liver disease (NAFLD) characterized by inflammation in the liver. For instance, in January 2022, Siemens Healthineers, a Germany-based Company, launched the Enhanced Liver Fibrosis (ELF) Test, The ELF Test is the first blood test granted De Novo marketing authorization by the FDA specifically for assessing disease progression in patients with NASH. Utilizing a simple blood sample, the ELF Test measures three biomarkers associated with liver fibrosis: hyaluronic acid, tissue inhibitor of metalloproteinases 1 (TIMP-1), and aminoterminal propeptide of type III procollagen (P3NP). This approach eliminates the need for invasive procedures like liver biopsies. The test is available nationwide through partnerships with Labcorp and Quest Diagnostics, ensuring broad access for patients and healthcare providers across the U.S.

Need data on a specific region in this market?

Non-Alcoholic Steatohepatitis Biomarkers Market Merger And Acquisition: Novo Nordisk And Echosens Forge Strategic Partnership To Advance Early Diagnosis And Awareness Of Non-Alcoholic Steatohepatitis (NASH)

In June 2022, Novo Nordisk A/S, a Denmark-based pharmaceutical company partnered with Echosens SA. With this partnership, the companies intend to promote non-alcoholic steatohepatitis (NASH) early diagnosis and raise disease awareness among patients, medical professionals, and other stakeholders. Echosens SA is a France-based manufacturer of therapeutic monitoring and diagnostic devices.

Regional Analysis For The Global Non-Alcoholic Steatohepatitis Biomarkers Market

North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-Alcoholic Steatohepatitis Biomarkers Market?

The non-alcoholic steatohepatitis biomarkers market consists of sales of biomarkers such as apolipoprotein A1, apolipoprotein B, leptin and adiponectin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Non-Alcoholic Steatohepatitis Biomarkers Industry?

The non-alcoholic steatohepatitis biomarkers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis biomarkers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Non-Alcoholic Steatohepatitis Biomarkers Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $1.68 billion
Revenue Forecast In 2034 $3.81 billion
Growth Rate CAGR of 22.6% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses Subsegments: 1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-
4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Non-Alcoholic Steatohepatitis Biomarkers Market Characteristics

3. Non-Alcoholic Steatohepatitis Biomarkers Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Non-Alcoholic Steatohepatitis Biomarkers Growth Analysis And Strategic Analysis Framework

5.1. Global Non-Alcoholic Steatohepatitis Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Non-Alcoholic Steatohepatitis Biomarkers Market Growth Rate Analysis

5.4. Global Non-Alcoholic Steatohepatitis Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Non-Alcoholic Steatohepatitis Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Non-Alcoholic Steatohepatitis Biomarkers Total Addressable Market (TAM)

6. Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation

6.1. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hepatic Fibrosis Biomarkers

Serum Biomarkers

Oxidative Stress Biomarkers

Apoptosis Biomarkers

Other Types

6.2. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hypertension

Heart Disease

High Blood Lipid

Type 2 Diabetes

Obesity

6.3. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Research Institutes And Academics

Diagnostic Centres

Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs)

Hospitals And Clinics

Other End-Uses

6.4. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Hepatic Fibrosis Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hyaluronic Acid

Procollagen III N-terminal Propeptide (PIIINP)

Fibrosis-4 (FIB-4) Index

6.5. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Serum Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Alanine Aminotransferase (ALT)

Aspartate Aminotransferase (AST)

Adiponectin

6.6. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Oxidative Stress Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Malondialdehyde (MDA)

8-Isoprostane

Advanced Oxidation Protein Products (AOPP)

6.7. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Apoptosis Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Caspase-3

Cytochrome c

Liver Inhibitory Protein (LIP)

6.8. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Metabolomic Biomarkers

Genetic Biomarkers

Inflammatory Biomarkers

7. Non-Alcoholic Steatohepatitis Biomarkers Market Regional And Country Analysis

7.1. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market

8.1. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Alcoholic Steatohepatitis Biomarkers Market

9.1. China Non-Alcoholic Steatohepatitis Biomarkers Market Overview

9.2. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Alcoholic Steatohepatitis Biomarkers Market

10.1. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Alcoholic Steatohepatitis Biomarkers Market

11.1. Japan Non-Alcoholic Steatohepatitis Biomarkers Market Overview

11.2. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Alcoholic Steatohepatitis Biomarkers Market

12.1. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market

13.1. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market

14.1. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market Overview

14.2. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market

15.1. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market Overview

15.2. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Alcoholic Steatohepatitis Biomarkers Market

16.1. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Alcoholic Steatohepatitis Biomarkers Market

17.1. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Alcoholic Steatohepatitis Biomarkers Market

18.1. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Alcoholic Steatohepatitis Biomarkers Market

19.1. Italy Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Alcoholic Steatohepatitis Biomarkers Market

20.1. Spain Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market

21.1. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market Overview

21.2. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Alcoholic Steatohepatitis Biomarkers Market

22.1. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Alcoholic Steatohepatitis Biomarkers Market

23.1. North America Non-Alcoholic Steatohepatitis Biomarkers Market Overview

23.2. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Alcoholic Steatohepatitis Biomarkers Market

24.1. USA Non-Alcoholic Steatohepatitis Biomarkers Market Overview

24.2. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Alcoholic Steatohepatitis Biomarkers Market

25.1. Canada Non-Alcoholic Steatohepatitis Biomarkers Market Overview

25.2. Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Alcoholic Steatohepatitis Biomarkers Market

26.1. South America Non-Alcoholic Steatohepatitis Biomarkers Market Overview

26.2. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market

27.1. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market

28.1. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market Overview

28.2. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Alcoholic Steatohepatitis Biomarkers Market

29.1. Africa Non-Alcoholic Steatohepatitis Biomarkers Market Overview

29.2. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape And Company Profiles

30.1. Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape

30.2. Non-Alcoholic Steatohepatitis Biomarkers Market Company Profiles

30.2.1. Genfit SA Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Prometheus Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Siemens Medical Solutions USA Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. BioPredictive Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Quest Diagnostics Overview, Products and Services, Strategy and Financial Analysis

31. Non-Alcoholic Steatohepatitis Biomarkers Market Other Major And Innovative Companies

31.1. AstraZeneca Plc.

31.2. Laboratory Corporation of America Holdings

31.3. Pfizer Inc.

31.4. Bristol-Myers Squibb Company

31.5. NGM Biopharmaceuticals Inc.

31.6. Gilead Sciences Inc.

31.7. Perspectum Diagnostics Ltd.

31.8. One Way Liver SL

31.9. Enterome SA

31.10. Echosens SA

31.11. Cisbio Bioassays SAS

31.12. Celerion Inc.

31.13. Boehringer Ingelheim GmbH Inc.

31.14. Exalenz Bioscience Ltd.

31.15. Novartis AG

32. Global Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Biomarkers Market

34. Recent Developments In The Non-Alcoholic Steatohepatitis Biomarkers Market

35. Non-Alcoholic Steatohepatitis Biomarkers Market High Potential Countries, Segments and Strategies

35.1 Non-Alcoholic Steatohepatitis Biomarkers Market In 2029 - Countries Offering Most New Opportunities

35.2 Non-Alcoholic Steatohepatitis Biomarkers Market In 2029 - Segments Offering Most New Opportunities

35.3 Non-Alcoholic Steatohepatitis Biomarkers Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Hepatic Fibrosis Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Serum Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Oxidative Stress Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Apoptosis Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Genfit SA Financial Performance
  • Table 80: Prometheus Laboratories Inc. Financial Performance
  • Table 81: Siemens Medical Solutions USA Inc. Financial Performance
  • Table 82: BioPredictive Financial Performance
  • Table 83: Quest Diagnostics Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Hepatic Fibrosis Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Serum Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Oxidative Stress Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Apoptosis Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Genfit SA Financial Performance
  • Figure 80: Prometheus Laboratories Inc. Financial Performance
  • Figure 81: Siemens Medical Solutions USA Inc. Financial Performance
  • Figure 82: BioPredictive Financial Performance
  • Figure 83: Quest Diagnostics Financial Performance

Frequently Asked Questions

Non-alcoholic steatohepatitis (NASH) is a type of liver inflammation and damage caused by a build-up of fat in the liver. NASH biomarkers are used as diagnostic tools to assess the severity of non-alcoholic steatohepatitis and to assess liver damage. This damages the liver cells and inflames the liver, which can result in cirrhosis (liver scarring) and liver failure. Biomarkers refer to a particular quality that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment. For further insights on this market, request a sample here

The market major growth driver - Rising Liver Cancer Prevalence Fuels Expansion Of Non-Alcoholic Steatohepatitis Biomarkers Market. For further insights on this market, request a sample here

The non-alcoholic steatohepatitis biomarkers market size has grown exponentially in recent years. It will grow from $1.36 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 23.9%. The growth in the historic period can be attributed to diabetes and metabolic syndrome, awareness and screening programs, liver biopsy limitations, regulatory support, shift towards personalized medicine, clinical trials in NASH. The non-alcoholic steatohepatitis biomarkers market size is expected to see exponential growth in the next few years. It will grow to $3.81 billion in 2029 at a compound annual growth rate (CAGR) of 22.6%. The growth in the forecast period can be attributed to emergence of novel therapies, expansion of precision medicine approaches, patient advocacy initiatives, integration of multi-omics data, enhanced patient engagement. Major trends in the forecast period include telemedicine and remote monitoring, innovative diagnostic platforms, global collaborations in research, technological advancements in biomarker discovery, integration of artificial intelligence (AI), inclusion of imaging biomarkers. For further insights on this market, request a sample here

The non-alcoholic steatohepatitis biomarkersmarket covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers For further insights on this market,
request a sample here

North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the non-alcoholic steatohepatitis biomarkers market include Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine . For further insights on this market, request a sample here.

Major trends in this market include Advancements In Nis4 Technology Pave The Way For Innovative Blood-Based Molecular Diagnostic Test. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Back to top WhatsApp icon